Skip to main content
. 2020 Jul 9;10(18):8382–8399. doi: 10.7150/thno.45391

Figure 1.

Figure 1

PTX embedded with nanomicelle exerts immune depended tumor control. A Schematic representation of PEG-PDLLA-paclitaxel nanomicelle. B-F Mice bearing CT26 were treated using PTX (10 mg/kg) embedded with or without nanomicelle for five times and the tissue was harvest on day 20. B The tumor growth after treatment, n = 5 mice per group. C The percentage of T cells (CD3+) in PBMC after treatment, n = 4 mice per group. D The percentage of CD11c+ cells in draining lymph node after treatment, n = 4 mice per group. E The percentage of total immune cells (CD45+) and T cells (CD3+) in tumor after treatment, n = 4 mice per group. F The percentage of dentritic cells (CD11c+) in tumor after treatment, n = 4 mice per group. G CT26 tumor growth in immune deficiency mice after nano-PTX (10 mg/kg) treatment with low dose, n = 8 mice per group. H The percentage of apoptotic immune cells in peripheral blood on day 1 after treatment, n = 4 mice per group. Mean ±SEM was shown. * P < 0.05, ** P < 0.01, ns (no statistical significance).